At a glance
ClinicalIndex Comparison Record- ✓Age ≥18 years (≥19 in South Korea)
- ✓ECOG performance status 0 or 1
- ✓Adequate renal and hepatic function
- ✓Adequate hematologic parameters without transfusional support
- ✕Pregnant or lactating females
- ✕Prior anti-cancer monoclonal antibody within 4 weeks of Day 1 or unrecovered adverse events from earlier agents
- ✕Active second malignancy
- ✕Known active Hepatitis B or Hepatitis C
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
In Brief
A Phase 2 clinical trial evaluating Sacituzumab Govitecan-hziy, Pembrolizumab, and 7 other interventions for Metastatic Urothelial Cancer. Currently recruiting, targeting 827 participants across 135 sites in 9 countries.
Signals
Detailed Summary
The objective of this study is to evaluate the efficacy and safety of sacituzumab govitecan-hziy monotherapy and with novel combinations in participants with metastatic urothelial cancer (mUC).
Study Details
Timeline
Interventions
Administered intravenously.
Administered per package insert
Administered per package insert
Administered per package insert
Administered intravenously
Administered per package insert
Administered per package insert
Administered intravenously
Administered intravenously